TELOMIR PHARMACEUTICALS INC(NASDAQ:TELO) stock Price, Quote, News and Overview

TELO Quote and Key Statistics

TELOMIR PHARMACEUTICALS INC

NASDAQ:TELO (1/22/2025, 11:52:19 AM)

5.15

+0.22 (+4.46%)

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS SubIndustryPharmaceuticals

Statistics

52 Week HighN/A

52 Week LowN/A

Market Cap152.49M

Shares29.61M

Float16.98M

Yearly DividendN/A

Dividend YieldN/A

PEN/A

Fwd PEN/A

Earnings (Next)N/A N/A

IPO02-09 2024-02-09

TELO Financial Highlights

		Industry Rank	Sector Rank
PM (TTM)	N/A
ROA	-2803.88%
ROE	-6608.95%
Debt/Equity	0

Chartmill High Growth Momentum

EPS Q2Q%-237.2%

Sales Q2Q%N/A

EPS 1Y (TTM)-593.13%

Revenue 1Y (TTM)N/A

Chartmill FA Analysis

Valuation

Growth

Profitability

Health

Dividend

TELO Performance and Technical Analysis

Chartmill TA Rating

Chartmill Setup Rating

TELOMIR PHARMACEUTICALS INC / TELO Daily stock chart

TELO Ownership and Analysts

Ownership

Inst Owners1.26%

Ins Owners19.29%

Short Float %7.5%

Short Ratio6.15

Analysts

AnalystsN/A

Price Target12.39 (140.58%)

EPS Next Y-15.05%

Revenue Next YearN/A

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TELO Latest News and Analysis

15 days ago - ACCESSWIRE

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

a month ago - ACCESSWIRE

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

a month ago - Benzinga

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

Telomir-1 shows potential as a treatment for Wilson's disease and related disorders, with promising preclinical results and potential for orphan drug designation.

a month ago - ACCESSWIRE

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

2 months ago - Benzinga

Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?

Telomir Pharmaceuticals unveils preclinical data on Telomir-1, highlighting its potential in Type 2 diabetes, aging, and inflammatory diseases.

2 months ago - ACCESSWIRE

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

About TELO

Company Profile

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The company is headquartered in Tampa, Florida and currently employs 1 full-time employees. The company went IPO on 2024-02-09. The firm operates as pre-clinical-stage pharmaceutical company focused on developing TELOMIR-1 small molecule to lengthen the deoxyribonucleic acid’s (DNA) protective telomere caps to affect age reversal. The company selectively affects the processes that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis and cancer.

Company Info